JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verel, I.
Right arrow Articles by van Dongen, G. A.M.S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verel, I.
Right arrow Articles by van Dongen, G. A.M.S

89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies

Iris Verel, MS1, Gerard W.M. Visser, PhD2, Ronald Boellaard, PhD3, Marijke Stigter-van Walsum, BS1, Gordon B. Snow, MD, PhD1 and Guus A.M.S van Dongen, PhD1

1 Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
2 Radionuclide Center, VU University, Amsterdam, The Netherlands
3 Department of Nuclear Medicine/PET Center, VU University Medical Center, Amsterdam, The Netherlands



View larger version (13K):

[in a new window]
 
FIGURE 1. Schematic representation of premodification and postlabeling of mAbs with 89Zr. Step 1 is synthesis of N-sucDf, as described in Materials and Methods. Step 2 is complexation of N-sucDf with Fe(III). N-sucDf (9 mg, 13.6 µmol) is dissolved in 3 mL of 0.9% NaCl, containing 60 µL of 0.1 mol/L Na2CO3 (final pH 6.5–7.0). To this solution, 300 µL (14.8 µmol) of FeCl3 solution (8 mg/mL in 0.1 mol/L HCl) is added. Step 3 is esterification of N-sucDf-Fe. After 10 min, to N-sucDf-Fe solution are added 300 µL (0.36 mmol) of TFP solution (200 mg/mL in MeCN) and 120 mg (0.63 mmol) of solid EDC (final pH 5.8–6.0). After 45 min of incubation, reaction mixture is loaded onto conditioned Sep-Pak C18 cartridge (Waters), followed by washing with 60 mL of sterile water for injection. TFP-N-sucDf-Fe is eluted from Sep-Pak cartridge with 1.5 mL of MeCN. Step 4 is conjugation of TFP-N-sucDf-Fe to mAb. To 1 mL (33 nmol) of mAb solution (5 mg/mL), pH 9.5–9.8 (adjusted with 0.1 mol/L Na2CO3), 20 µL (63 nmol) of TFP ester solution (2.5 mg/mL in MeCN) are added to obtain final chelate:mAb ratio of 1:1 (based on 54% reaction efficiency). After 30 min, 2 times 25 µL of gentisic acid solution (100 mg/mL in 0.32 mol/L Na2CO3) are added to reaction mixture and pH is adjusted to 4.3–4.5 with 4 times 6 µL of 0.25 mol/L H2SO4. Step 5 is removal of Fe(III) from mAb-N-sucDf-Fe. To reaction mixture, 50 µL (3.3 µmol) of an EDTA solution (25 mg/mL) is added and solution is incubated for 30 min at 35°C (final pH 4.3–4.5). After 30 min, EDTA, TFP, iron (as [Fe(III)EDTA]-), and unreacted hydrolyzed ester (N-sucDf) are removed by gel filtration using PD-10 column (eluent: 0.9% NaCl/gentisic acid [5 mg/mL], pH 5): First 2.6 mL (containing reaction volume and first 1.5 mL) are discarded, and modified mAb is collected in next 2 mL. Step 6 is labeling of mAb-N-sucDf with 89Zr. To 600 µL of 89Zr oxalic acid solution (1 mol/L oxalic acid), 130 µL of 0.9% NaCl, 270 µL of 2 mol/L Na2CO3, and 3 mL of 0.5 mol/L HEPES (pH 7.2–7.4) are added, followed by 2 mL (33 nmol) of modified mAb solution (2.5 mg/mL in 0.9% NaCl/gentisic acid [5 mg/mL], pH 5), final pH 7.2–7.4. Reaction volume can be varied provided amounts of oxalic acid, Na2CO3, and HEPES buffer are adjusted accordingly. After 30 min, reaction mixture (6 mL) is divided over 3 PD-10 columns (eluent: 0.9% NaCl/gentisic acid [5 mg/mL], pH 5): First 2.5 mL (2-mL sample volume and first 0.5 mL) are discarded, and radiolabeled mAb is collected in next 3 mL. Bold arches represent -(CH2)2CONH(CH2)5-. Desferal (Df) (Novartis) is term used instead of desferrioxamine B, and Df-Fe is term used to represent corresponding iron(III) complex (ferrioxamine).

 


View larger version (20K):

[in a new window]
 
FIGURE 2. HPLC profiles (absorbance at 430 nm and radioactivity after fraction collection) during synthesis of TFP-N-sucDf ester and preparation of mAb-N-sucDf after reaction of N-sucDf with 59Fe-FeCl3 (A), after esterification of N-sucDf-59Fe-Fe (B), after reaction of TFP-N-sucDf-59Fe-Fe with mAb (C), and after removal of iron from mAb-N-sucDf-59Fe-Fe with EDTA (D). Analyses were performed with Chromspher (Chrompack) 5 C18 column (A and B) or Superdex (Pharmacia Biotech) 200 HR column (C and D). Peak 1 = unreacted 59Fe-FeCl3 (retention time, 3.3 min; reaction performed with an excess of 1.1 to 1); peak 2 = N-sucDf-59Fe-Fe (retention time, 16.7 min for A and B and 39 min for C); peak 3 = TFP-N-sucDf-59Fe-Fe (retention time, 25.9 min); peak 4 = mAb-N-sucDf-59Fe-Fe (retention time, 23 min); peak 5 = [59Fe-Fe(III)EDTA]- (retention time, 38 min).

 


View larger version (23K):

[in a new window]
 
FIGURE 3. Biodistribution of cmAb U36-N-sucDf-89Zr (hatched bars, n = 4) and cmAb U36-SMCC-SATA-Df-89Zr (open bars, n = 4). Each conjugate (100 µg of mAb; 0.37 MBq) was injected into retroorbital plexus of HNX-OE–bearing nude mice. At 24 h (A), 48 h (B), and 72 h after injection (C), mice were bled, sacrificed, and dissected, and radioactivity levels (%ID/g ± SEM) of blood, tumor, organs, and gastrointestinal contents were assessed.

 


View larger version (15K):

[in a new window]
 
FIGURE 4. In vitro stability of cmAb U36-N-sucDf-89Zr and cmAb U36-SMCC-SATA-Df-89Zr, monitored by HPLC. Conjugates were incubated for 24 h at 37°C: cmAb U36-N-sucDf-89Zr in human serum (A); cmAb U36-SMCC-SATA-Df-89Zr in human serum (B); cmAb U36-SMCC-SATA-Df-89Zr in HSA, at pH 9 (C); and cmAb U36-SMCC-SATA-Df-89Zr in HSA, at pH 9 with an excess of L-cysteine (D). Retention times of IgG and HSA are indicated.

 


View larger version (107K):

[in a new window]
 
FIGURE 5. HNX-OE–bearing nude mouse, injected with cmAb U36-N-sucDf-89Zr (100 µg of mAb; 3.7 MBq). (A–C) Coronal (upper) and transaxial (lower) PET images were obtained from same mouse at 24 h (A), 48 h (B), and 72 h (C). Image planes are those for which both tumors of same animal were visible. (D) Photographs of imaged mouse and excised tumors (left, 47 mg; right, 45 mg).

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.